TY  - GEN
AU  - Ziepert,Marita
AU  - Hasenclever,Dirk
AU  - Kuhnt,Evelyn
AU  - Glass,Bertram
AU  - Schmitz,Norbert
AU  - Pfreundschuh,Michael
AU  - Loeffler,Markus
TI  - Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
SN  - 1527-7755
PY  - 2010///0520
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antigens, CD20
KW  - immunology
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Computer Simulation
KW  - Cyclophosphamide
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Female
KW  - Health Status Indicators
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lymphoma, B-Cell
KW  - diagnosis
KW  - Male
KW  - Middle Aged
KW  - Predictive Value of Tests
KW  - Prednisone
KW  - Proportional Hazards Models
KW  - Prospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Rituximab
KW  - Time Factors
KW  - Treatment Outcome
KW  - Vincristine
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2009.26.2493
ER  -